Advances in Direct-to-Biology

AJ Ratcliffe, CSO of Domainex, presents Advances in Direct-to-Biology. While traditional medicinal chemistry often experiences bottlenecks associated with the time and cost constraints of purifying large numbers of synthesised compounds, D2B bypasses this limitation through direct testing on biological assays. By ensuring that full purification and resynthesis are only done on promising compounds, D2B significantly reduces cycle times, costs, and the environmental footprint of the purification process for compounds.